Study of the Intermediate Metabolism in Children With Acute Lymphoblastic Leukemia (ALL)

Study of the Intermediate Metabolism in Children With Acute Lymphoblastic Leukemia

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03035344

Enrollment

Registered

2017-01-30

Start date

2015-05-31

Completion date

2018-11-30

Last updated

2017-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lymphoblastic Leukemia, Pediatric, Metabolism Disorder

Brief summary

Study of the intermediate metabolism in children diagnosed with ALL compared to healthy matched controls.

Detailed description

The primary cause of this study is to investigate the changes that ALL may cause to the metabolome of pediatric patients, in order to better understand its mechanism of action and target metabolic pathways for potential therapies.

Interventions

OTHERMetabolome study

Metabolome study in ALL patients compared to healthy controls

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Months to 16 Years

Healthy volunteers

Inclusion criteria

* Sex: all * Minimum age: 1 year * Maximum age: 16 years * The study accepts healthy volunteers as matched controls for the patinets. * Inclusion criteria: 1)Children diagnosed with ALL 2) Diagnosis confirmed with bone marrow biopsy 3) Sampling before the initiation of therapy 4) Informed consent signed *

Exclusion criteria

1) Children with a known chronic illness before ALL diagnosis 2) ALL remission 3) Not signed informed consent * Population description: Patients are recruited from the Pediatric Hematology/Oncology Department of Aristotle University of Thessaloniki (AHEPA hospital) and from the Pediatric Hematology/ Oncology Department of Ippokration Hospital, that host all children diagnosed with ALL in nothern Greece. Matched controls are recruited from outpatient clinic of the 2nd and 4th Pediatric Department of Aristotle University of Thessaloniki. * Sampling method: Non-probability sample

Design outcomes

Primary

Measure	Time frame	Description
Difference in measurement of aminoacids and organic acids between ALL patients and healthy matched controls.	Up to six months	The title of aminoacids in blood and urine and of organic acids in urine will be measured through Tandem Mass Spectrometry

Countries

Greece

Contacts

Primary ContactMaria T. Papadopoulou, MD

mtpapado@gmail.com6932343539

Backup ContactAthanassios Evangeliou, Prof

00302313323916

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026